阻断IL-17细胞因子通过增强FOXO1和ATF4活性促进皮质骨缺损模型中的骨愈合
研究在去卵巢骨质疏松小鼠股骨皮质骨缺损模型中,比较IL-17中和抗体与anti-RANKL、PTH和阿仑膦酸钠对新骨再生的作用;micro-CT显示anti-IL-17在10天和21天促进骨愈合,效果显著优于Ovx、anti-RANKL和ALN,与PTH相当。
要点
- Anti-IL-17抗体在去卵巢小鼠股骨缺损模型中促进骨愈合。
- 第10天和第21天愈合效果显著优于Ovx、anti-RANKL和ALN,与PTH相当。
- Anti-IL-17增强成骨标志物表达并降低损伤部位氧化应激。
核心结论
- 中和IL-17抗体在骨质疏松性骨折中具有骨愈合与骨再生潜力。
研究设计与样本
- 雌性BALB/c小鼠行去卵巢或假手术,1个月后建立股骨中段0.6 mm钻孔缺损模型。
- 次日开始分别给予anti-IL-17、anti-RANKL、PTH或阿仑膦酸钠治疗3天、10天或21天。
- 处死后取股骨行micro-CT扫描、共聚焦显微镜及基因和蛋白表达研究。
主要发现
- Micro-CT分析显示anti-IL-17抗体在第10天和第21天促进骨愈合。
- Anti-IL-17的愈合效果显著优于Ovx、anti-RANKL抗体和ALN,与PTH相当。
- Calcein标记研究显示anti-IL-17增强新骨再生。
- Anti-IL-17治疗增强成骨标志物表达并降低损伤部位氧化应激。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We determine the effect of interleukin (IL)-17 neutralizing antibody on new bone regeneration. Anti-IL-17 antibody promoted new bone regeneration in cortical bone defect model by augmenting FOXO1 and ATF4 activity thereby decreasing oxidative stress. Our study demonstrates the bone healing and regeneration potential of neutralizing IL-17antibody in osteoporotic fractures. INTRODUCTION: The immune system plays important role in the fracture healing process. However, fracture healing is prolonged in disorders associated with systemic inflammation. Fracture healing is decelerated in osteoporosis, condition linked with systemic inflammation. Bone regeneration therapies like recombinant human BMP2 are associated with serious side effects. Studies have been carried out where agents like denosumab and infliximab enhance bone regeneration in osteoporotic conditions. Our previous studies show the osteoprotective and immunoprotective effects of neutralizing IL-17 antibody. Here, we determine the effect of IL-17 neutralizing antibody on new bone regeneration and compare its efficacy with known osteoporotic therapies. METHODS: For the study, female BALB/c mice were ovariectomized or sham operated and left for a month followed by a 0.6-mm drill-hole injury in femur mid-diaphysis. The treatment was commenced next day onwards with anti-IL-17, anti-RANKL (Receptor activator of nuclear factor kappa-B ligand), parathyroid hormone (PTH), or alendronate for a period of 3, 10, or 21 days. Animals were then autopsied, and femur bones were dissected out for micro-CT scanning, confocal microscopy, and gene and protein expression studies. RESULTS: Micro-CT analysis showed that anti-IL-17 antibody promoted bone healing at days 10 and 21, and the healing effect observed was significantly better than Ovx, anti-RANKL antibody, and ALN, and equal to PTH. Anti-IL-17 also enhanced new bone regeneration as assessed by calcein-labeling studies. Additionally, anti-IL-17 therapy enhanced expression of osteogenic markers and decreased oxidative stress at the injury site. CONCLUSION: Overall, our study demonstrates bone healing and regeneration potential of neutralizing IL-17 antibody in osteoporotic fractures.
引用
- Dixit M, Singh KB, Prakash R, et al. Functional block of IL-17 cytokine promotes bone healing by augmenting FOXO1 and ATF4 activity in cortical bone defect model. Osteoporos Int. 2017. PMID: 28341898. doi:10.1007/s00198-017-4012-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。